EGFR tyrosine kinase inhibitors (EGFR-TKIs) selectively block the EGFR signaling pathway, thereby improving survival in patients with NSCLC carrying EGFR mutations [4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.